@xconomy.com 6 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 year ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On